Physician profile
Aryan Caire
NPI 1841426186
$2,927.34
in general payments reported to CMS, 2019-2025
28 companies · $638 in 2025
The $638 reported for 2025 was more than what 78% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $764 · 2020: $118 · 2021: $50.66 · 2022: $359 · 2023: $563 · 2024: $435 · 2025: $638.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,636.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,635.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $569.96 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $339.06 | 2019-2025 | Repatha, Otezla, Repatha |
| Pfizer INC. | $317.47 | 2019-2025 | |
| Lilly USA, LLC | $282.51 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Boehringer Ingelheim Pharmaceuticals, INC. | $203.48 | 2019-2024 | Jardiance |
| Abbvie INC. | $192.78 | 2022-2025 | Vraylar, Ubrelvy |
| Glaxosmithkline, LLC. | $172.63 | 2022-2023 | Shingrix, Arexvy |
| Astellas Pharma US INC | $154.72 | 2019-2025 | Veozah |
| Novo Nordisk INC | $135.54 | 2019-2024 | Rybelsus, Ozempic, Wegovy |
| Teva Pharmaceuticals USA, INC. | $111.86 | 2019-2025 | Ajovy |
| Novartis Pharmaceuticals Corporation | $65.73 | 2019 | |
| Abbott Laboratories | $42.45 | 2023-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $38.46 | 2022-2024 | Trulance, Xifaxan |
| Exact Sciences Corporation | $30.68 | 2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $30.44 | 2022-2023 | Quviviq |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Healthtronics Stone Solutions, LLC | $23.43 | 2019 | |
| Merck Sharp & Dohme LLC | $22.93 | 2019 | |
| Gilead Sciences, INC. | $22.15 | 2025 | Yeztugo |
| Nevro Corp. | $22.09 | 2024 | Senza |
| Boston Scientific Corporation | $21.26 | 2024 | Solyx Sis System |
| Xeris Pharmaceuticals, INC. | $17.69 | 2024 | Gvoke Hypopen |
| Eisai INC. | $17.12 | 2025 | |
| Sumitomo Pharma America, INC. | $16.70 | 2024 | Gemtesa |
| Genentech USA, INC. | $16.04 | 2019 | |
| Sanofi-Aventis U.S. LLC | $15.81 | 2021 | |
| Nestle Healthcare Nutrition INC. | $14.86 | 2022 | |
| Sanofi Pasteur INC. | $14.78 | 2019 | |
| Janssen Pharmaceuticals, INC | $14.71 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aryan Caire listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.